Heck I, Lüderitz B, Müller H M, Esser H
University Medical Clinic, Bonn, Germany.
Clin Ther. 1995 Mar-Apr;17(2):270-9. doi: 10.1016/0149-2918(95)80025-5.
In a double-blind study, 116 patients (mean age, 57.6 years) with mild-to-moderate chronic congestive heart failure who were in sinus rhythm were randomly assigned to receive 25 mg of captopril twice daily (up to 50 mg twice daily, if needed) plus hydrochlorothiazide (HCTZ) (group 1) or 0.1 mg of digoxin twice daily plus HCTZ (group 2) for 12 months. During a 3- to 4-week pretreatment stabilization period, group 1 received a mean of 37.7 mg of HCTZ daily and group 2 received 34.9 mg daily. After 6 weeks and 12 months of treatment, improvement was noted in both treatment groups on five measures of cardiac function: exercise tolerance, left ventricular end-diastolic diameter (LVEDD), ejection fraction, blood pressure, and heart rate. At 12 months, significantly greater improvement was noted in group 1 than in group 2 in exercise tolerance (from 329 seconds at baseline to 445 seconds at 12 months in group 1 and from 353 to 427 seconds in group 2; P < 0.05); LVEDD (from 60.5 to 56.5 mm in group 1 and from 60.3 to 57.9 mm in group 2; P < 0.05); and blood pressure (from 103.5 to 95.6 mm Hg in group 1 and from 101.9 to 97.0 mm Hg in group 2; P < 0.03). Clinical severity (New York Heart Association class) improved in both groups; 52% of the patients in group 1 and 41% in group 2 dropped an average of one functional class (P < 0.01). The results indicate that captopril combined with a diuretic is an effective initial treatment for patients with mild-to-moderate congestive heart failure.
在一项双盲研究中,116例轻度至中度慢性充血性心力衰竭且心律为窦性的患者(平均年龄57.6岁)被随机分配,分别接受每日两次25毫克卡托普利(必要时可增至每日两次50毫克)加氢氯噻嗪(HCTZ)(第1组),或每日两次0.1毫克地高辛加氢氯噻嗪(第2组)治疗,为期12个月。在为期3至4周的预处理稳定期内,第1组平均每日接受37.7毫克氢氯噻嗪,第2组平均每日接受34.9毫克。治疗6周和12个月后,两个治疗组在五项心功能指标上均有改善:运动耐量、左心室舒张末期内径(LVEDD)、射血分数、血压和心率。在12个月时,第1组在运动耐量方面的改善明显大于第2组(第1组从基线时的329秒增至12个月时的445秒,第2组从353秒增至427秒;P<0.05);LVEDD(第1组从60.5毫米降至56.5毫米,第2组从60.3毫米降至57.9毫米;P<0.05);以及血压(第1组从103.5毫米汞柱降至95.6毫米汞柱,第2组从101.9毫米汞柱降至97.0毫米汞柱;P<0.03)。两组的临床严重程度(纽约心脏协会分级)均有所改善;第1组52%的患者和第2组41%的患者平均降低了一个功能级别(P<0.01)。结果表明,卡托普利联合利尿剂是轻度至中度充血性心力衰竭患者有效的初始治疗方法。